{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:13:44Z","timestamp":1781770424921,"version":"3.54.5"},"reference-count":82,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Janssen Scientific Affairs, LLC."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Teclistamab (TEC) is the first B-cell maturation antigen-directed bispecific antibody approved in 2022 by the European Medicines Agency and Food and Drug Administration for triple-class exposed relapsed\/refractory multiple myeloma (RRMM). Objectives: As TEC is increasingly used in real-world (RW) settings, this study seeks to gather existing RW evidence on effectiveness, safety, healthcare resource utilization, and clinical practices associated with TEC. Methods: A systematic literature review was performed to identify RW observational studies of TEC-treated adults with RRMM from 2023 to June 2024. Results: Sixty-one records representing 41 unique studies were included; sample sizes ranged from 8 to 572 patients. Where reported, median follow-up ranged from 2.3 to 33.6 months, and &gt;65% of the patients would have been ineligible for the pivotal trial of TEC (MajesTEC-1) in all but one study. In eight studies with \u226550 patients and \u22653 months follow-up, overall response rates were 59\u201366% and cytokine release syndrome (CRS) rates were 18\u201364%. Tocilizumab use for CRS management was reported in 14 studies, with two indicating CRS rates of 13% and 26% when used prophylactically. Survival and infection outcomes showed wide variability due to short follow-up in most studies. Conclusions: Overall, early RW effectiveness and safety outcomes of TEC were comparable to findings from MajesTEC-1.<\/jats:p>","DOI":"10.3390\/cancers17071235","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T03:23:07Z","timestamp":1743996187000},"page":"1235","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-World Evidence Evaluating Teclistamab in Patients with Relapsed\/Refractory Multiple Myeloma: A Systematic Literature Review"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-1819","authenticated-orcid":false,"given":"Benjamin","family":"Derman","sequence":"first","affiliation":[{"name":"Section of Hematology\/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlyn","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Steinfield","sequence":"additional","affiliation":[{"name":"Precision AQ, Boston, MA 02110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence R.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Precision AQ, Vancouver, BC V6J 1H2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Lin","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingcao","family":"Wu","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1742-1448","authenticated-orcid":false,"given":"Mariana","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Janssen-Cilag S.A., 28703 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Fowler","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agne","family":"Paner-Straseviciute","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Kim","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Doyle","sequence":"additional","affiliation":[{"name":"Janssen Sciences Ireland, D24WR89 Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Marshall","sequence":"additional","affiliation":[{"name":"Janssen Global Services, LLC, Raritan, NJ 08869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Cheadle","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Keeping","sequence":"additional","affiliation":[{"name":"Precision AQ, Vancouver, BC V6J 1H2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane Jijun","family":"Liu","sequence":"additional","affiliation":[{"name":"Illinois CancerCare, Peoria, IL 61615, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"ref_1","unstructured":"National Cancer Institute (2024, August 02). SEER Cancer Stat Facts: Myeloma, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Padala, S.A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., and Ajebo, G.H. (2021). Epidemiology, Staging, and Management of Multiple Myeloma. Med. Sci., 9.","DOI":"10.3390\/medsci9010003"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2017.12.012","article-title":"Prolonged Duration of Therapy Is Associated with Improved Survival in Patients Treated for Relapsed\/Refractory Multiple Myeloma in Routine Clinical Care in the United States","volume":"18","author":"Hari","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40487-022-00198-0","article-title":"Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States","volume":"10","author":"Jagannath","year":"2022","journal-title":"Oncol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","article-title":"Relapsed refractory multiple myeloma: A comprehensive overview","volume":"33","author":"Bazarbachi","year":"2019","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-021-00344-2","article-title":"The changing landscape of relapsed and\/or refractory multiple myeloma (MM): Fundamentals and controversies","volume":"10","author":"Encinas","year":"2022","journal-title":"Biomark. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2023-174270","article-title":"Real-World Treatment Outcomes of Teclistamab Under an Outpatient Model for Step-up Dosing Administration","volume":"142","author":"Sandahl","year":"2023","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1182\/blood-2023-187479","article-title":"Panel Interview of Oncology Practices with Emergent Experience of Teclistamab in the Real World: The Tec-Pioneer Study","volume":"142","author":"Derman","year":"2023","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e605007f","DOI":"10.1097\/01.HS9.0000970664.60500.7f","article-title":"P940: An outpatient model for teclistamab step-up dosing administration\u2014Initial experiences at fox chase cancer center BMT program","volume":"7","author":"Styler","year":"2023","journal-title":"HemaSphere"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"308.e1","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and Efficacy of Teclistamab in Patients with Relapsed\/Refractory Multiple Myeloma: A Real-World Experience","volume":"30","author":"Dima","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(03)01077-5","article-title":"Management of multiple myeloma: A systematic review and critical appraisal of published studies","volume":"4","author":"Kumar","year":"2003","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.clinthera.2018.01.014","article-title":"Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis","volume":"40","author":"Maiese","year":"2018","journal-title":"Clin. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Guyot, P., Ades, A.E., Ouwens, M.J.N.M., and Welton, N.J. (2012). Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol., 12.","DOI":"10.1186\/1471-2288-12-9"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/bloodadvances.2023011225","article-title":"CD8 effector T cells enhance response in BCMA-exposed and -na\u00efve multiple myeloma","volume":"8","author":"Firestone","year":"2023","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/bloodadvances.2024012724","article-title":"Patterns of CRS with teclistamab in relapsed\/refractory multiple myeloma with or without prior T-cell redirection therapy","volume":"8","author":"Hamadeh","year":"2024","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: Multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2023-182695","article-title":"Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies: An FDA Adverse Event Reporting System (FAERS) Database Study","volume":"142","author":"Gong","year":"2023","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Midha, S., Laubach, J., Mo, C., Sperling, A., Nadeem, O., Bianchi, G., Hartley-Brown, M., Ramsdell, L., Reyes, K., and Costello, P. (2023, January 27\u201330). Real world experience of patients treated with teclistamab: aBCMA-directed bispecific t-cell engaging therapy for multiple myeloma. Proceedings of the Internation Myeloma Society Annual Meeting and Exposition, Athens, Greece.","DOI":"10.1016\/S2152-2650(23)01653-1"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6683","DOI":"10.1182\/blood-2023-182754","article-title":"Characterization of Anthropometric Changes in Patients with Relapsed\/Refractory Myeloma Treated with BCMA Bispecific Antibody Teclistamab","volume":"142","author":"Nader","year":"2023","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","article-title":"Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Moreau","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_25","unstructured":"Banerjee, R., Chang, H.-Y., Lin, D., Fu, A.Z., Hester, L., Kim, N., Fowler, J., Walker, S., Gifkins, D., and Hearty, C. (2023, January 18\u201321). Real-World Patterns of Step-Up Dosing Period and Early Safety Outcomes in US Patients Treated with Teclistamab for Multiple Myeloma. Proceedings of the Lymphoma, Leukemia & Myeloma Congress, New York, NY, USA."},{"key":"ref_26","unstructured":"Banerjee, R., Chang, H.-Y., Lin, D., Harper, J.S., Fu, A.Z., Kim, N., Fowler, J., Fernandez, M., Doyle, M., and Min, E.E. (2024, January 15). Teclistamab (TEC) step-up dosing (SUD) and treatment dose schedule de-escalation in the real-world (RW) setting\u2014An analysis of multicenter electronic medical records. Proceedings of the European Hematology Association 2024, Barcelona, Spain."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2023-180421","article-title":"Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma","volume":"142","author":"Dima","year":"2023","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2023-180458","article-title":"Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study","volume":"142","author":"Dima","year":"2023","journal-title":"Blood"},{"key":"ref_29","first-page":"S384","article-title":"Safety and Efficacy of Teclistamab in Patients with Relapsed\/Refractory Multiple Myeloma: A Real-World Experience from the US Myeloma Innovations Research Collaborative (USMIRC)","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_30","first-page":"S384","article-title":"Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy and Teclistamab in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease: A Real-World Experience of the US Myeloma Innovations Research Collaborative (USMIRC)","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2023-187467","article-title":"Evaluating Tumor-Intrinsic and Patient-Specific Mechanisms of Resistance to Teclistamab in Anti-BCMA Exposed and Na\u00efve Multiple Myeloma","volume":"142","author":"Firestone","year":"2023","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e81198bb","DOI":"10.1097\/01.HS9.0000970752.81198.bb","article-title":"P962: Commercial Teclistamab in anti-BCMA therapy exposed relapsed refractory multiple myeloma patients: The MSKCC experience","volume":"7","author":"Firestone","year":"2023","journal-title":"HemaSphere"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1200\/JCO.2023.41.16_suppl.8049","article-title":"Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies","volume":"41","author":"Firestone","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1182\/blood-2023-174875","article-title":"Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study","volume":"142","author":"Mohan","year":"2023","journal-title":"Blood"},{"key":"ref_35","unstructured":"Matthew, J., Pianko, J.H., Lin, D., Chang, H.-Y., Nina, K., Harper, J.S., Fowler, J., Fernandez, M., Doyle, M., and Hester, L. (2024, January 15). Real-world schedule de-escalation of teclistamab in patients with relapsed or refractory multiple myeloma\u2014A US national healthcare claims analysis. Proceedings of the European Hematology Association 2024, Barcelona, Spain."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1182\/blood-2023-180032","article-title":"Real-World Analysis of Teclistamab in 115 RRMM Patients from Germany","volume":"142","author":"Riedhammer","year":"2023","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S506","DOI":"10.1016\/S2152-2650(23)01466-0","article-title":"MM-527 Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)","volume":"23","author":"Maringanti","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_38","unstructured":"Yi, L.S.A., Brunaldi, L., Bansal, R., De Menezes Silva Corraes, A., Chhabra, S., Parrondo, R., Ailawadhi, S., Kastritis, E., Fotiou, D., and Popat, R. (2023, January 27\u201330). Real world evaluation of Teclistamab in patients with RRMM: Results from the IMF Immunotherapy Database Project. Proceedings of the International Myeloma Society Annual Meeting and Exposition, Athens, Greece."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2023-190793","article-title":"Real-World Evaluation of Teclistamab for the Treatment of Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"142","author":"Asoori","year":"2023","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7536","DOI":"10.1200\/JCO.2024.42.16_suppl.7536","article-title":"Real-world schedule de-escalation of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Tan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Tan, C.R.C., Derkach, A., Maclachlan, K., Hultcrantz, M., Hassoun, H., Mailankody, S., Shah, U.A., Rajeeve, S., Shah, G.L., and Scordo, M. (2024, January 15). Real-world schedule de-escalation of teclistamab in patients with relapsed\/refractory multiple myeloma. Proceedings of the European Hematology Association 2024, Barcelona, Spain.","DOI":"10.1200\/JCO.2024.42.16_suppl.7536"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1182\/blood-2023-187086","article-title":"Tocilizumab Prophylaxis for Patients Treated with Teclistamab: A Single-Center Experience","volume":"142","author":"Kowalski","year":"2023","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1182\/blood-2023-189878","article-title":"Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration","volume":"142","author":"Marin","year":"2023","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1182\/blood-2023-178908","article-title":"Evolving Real-World Characteristics and Step-up Dosing Among Early Initiators of Teclistamab for Multiple Myeloma\u2014A National All-Payer Claims Database Study","volume":"142","author":"Banerjee","year":"2023","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1200\/JCO.2023.41.16_suppl.1533","article-title":"Outpatient practice utilization for CAR-T and T cell engager in patients with lymphoma and multiple myeloma","volume":"41","author":"Bansal","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_46","unstructured":"Kathy Mooney, N.A., Anderson, K., and Zukas, A. (2024, January 24\u201328). Taking a BiTE out of Hospital Admission Days Using a Team Approach to Managing Patients at Risk for Treatment Related Toxicities. Proceedings of the Oncology Nursing Society 2024, Washington DC, USA."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1182\/blood-2023-187889","article-title":"Identifying Causes of Unscheduled Healthcare Interactions and Changes to Patient Disposition in Individuals Receiving Outpatient Commercial Bispecific Antibody Therapy in Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"142","author":"Howard","year":"2023","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: The neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: Consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Usmani","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1182\/blood-2023-179727","article-title":"French Monocentric Experience of Outpatient Step-up Dosing of Teclistamab in Relapsed Refractory Multiple Myeloma","volume":"142","author":"Hebraud","year":"2023","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/03007995.2024.2352856","article-title":"Panel Interview of ONcology practices with Emergent Experience of teclistamab in the Real world: The TecPIONEER Study","volume":"40","author":"Derman","year":"2024","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S491","DOI":"10.1016\/S2152-2650(23)01439-8","article-title":"MM-344 Real-World Patient Profile and Step-Up Dosing Process of Early Initiators of Teclistamab for Multiple Myeloma (MM) in a Hospital Setting in the US: Premier Healthcare Database Study","volume":"23","author":"Tan","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_54","unstructured":"Scottish Intercollegiate Guidelines Network, and Health Improvement Scotland (2024, May 23). SIGN Search Filters. Available online: https:\/\/www.sign.ac.uk\/what-we-do\/methodology\/search-filters\/."},{"key":"ref_55","unstructured":"Wells, G.S., O\u2019Connell, D., Peterson, J., Welch, V., and Losos, M. (2016, October 01). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available online: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S536","DOI":"10.1016\/S2152-2650(23)01527-6","article-title":"CT-630 Real World Evaluation of Teclistamab: A Focus on Infections in Patients with Relapsed Refractory Multiple Myeloma (RRMM)","volume":"23","author":"Asoori","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood-2023-187186","article-title":"Outpatient Management of CAR-T and Teclistamab for Patients with Lymphoma and Multiple Myeloma","volume":"142","author":"Bansal","year":"2023","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1200\/JCO.2024.42.16_suppl.7520","article-title":"Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy","volume":"42","author":"Bansal","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_60","unstructured":"Deborah Bolton, A.B., Martin, J., and Monsale, S. (2024, January 24\u201328). Administration of Teclistamab Shortly after Food and Drug Administration Approval in a Community Hospital System. Proceedings of the Oncology Nursing Society Congress 2024, Washington DC, USA."},{"key":"ref_61","unstructured":"Catamero, D.D. (2023, January 27\u201330). Real world experience of teclistamab using a promptmanagement strategy for cytokine release syndrome. Proceedings of the International Myeloma Society Annual Meeting and Exposition, Athens, Greece."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.1200\/JCO.2024.42.16_suppl.7542","article-title":"Incidence of acute kidney injury in patients with relapsed and refractory multiple myeloma treated with teclistamab vs chimeric antigen receptor T-cell therapy","volume":"42","author":"Charkviani","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Beth Faiman, D.D., Duco, M., Rice, M., Rudoni, J., Anwer, F., Khouri, J., Mazzoni, S., Raza, S., Samaras, C., and Williams, L. (2023, January 27\u201330). Initial Report of a Single Institution Experience with Teclistamabfor Relapsed or Refractory Multiple Myeloma Including Prior BCMA. Proceedings of the International Myeloma Society Annual Meeting and Exposition, Athens, Greece.","DOI":"10.1016\/S2152-2650(23)01874-8"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e19504","DOI":"10.1200\/JCO.2024.42.16_suppl.e19504","article-title":"Real-world outcomes of teclistamab for the treatment of relapsed\/refractory multiple myeloma at UC San Diego Health: A single-institution experience","volume":"42","author":"Ghamsari","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_65","unstructured":"Melanie, R., Glenn, K.G., Bucknall, J., and Ricca, M. (2024, January 24\u201328). Teclistamab Early Discharge Program. Proceedings of the Oncology Nursing Society Congress 2024, Washington DC, USA."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1182\/blood-2023-181304","article-title":"Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial","volume":"142","author":"Gordon","year":"2023","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"S381","DOI":"10.1016\/j.jtct.2023.12.533","article-title":"\u2018Fast but Not so Furious\u2019: A Condensed but Safe and Cost-Effective Step-up Dosing Regimen of Teclistamab for Relapsed Refractory Multiple Myeloma","volume":"30","author":"Graf","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Grajales-Cruz, A.S.K., Blue, B., Hansen, D., Puglianini, O.C., Freeman, C., De Avila, G., Ochoa-Bayona, L., Liu, H., Nishihori, T. (2023, January 27\u201330). Safety and Efficacy of Standard of Care (SOC) Teclistamab (TEC) in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM), a single center experience. Proceedings of the International Myeloma Society Annual Meeting and Exposition, Athens, Greece.","DOI":"10.1016\/S2152-2650(23)01630-0"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood-2023-184928","article-title":"Teclistamab Induces Favorable Responses in Patients with Relapsed and Refractory Multiple Myeloma after Prior BCMA-Directed Therapy","volume":"142","author":"Castaneda","year":"2023","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Hamadeh, I.S., Shekarkhand, T., Rueda, C., Firestone, R., Wang, A., Korde, N., Hulcrantz, M., Lesokhin, A., Mailankody, S., and Hassoun, H. (2023, January 27\u201330). Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed\/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy. Proceedings of the International Myeloma Society Annual Meeting and Exposition, Athens, Greece.","DOI":"10.1016\/S2152-2650(23)01631-2"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood-2023-180283","article-title":"Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed\/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy","volume":"142","author":"Hamadeh","year":"2023","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Kawasaki, Y., Steele, A.P., Rosenberg, A., and Guglielmo, J. (2024, January 3\u20136). Safety Outcomes of Teclistamab Accelerated Dose Escalation. Proceedings of the Hematology\/Oncology Pharmacy Association 2024, Tampa, FL, USA.","DOI":"10.1177\/10781552241268429"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Swarup Kumar, K.H., Clark, J., Soto, A.A., and Rounds, A. (2023, January 27\u20133). Early outcomes and therapy modification strategies in Multiple Myeloma patients treated with teclistamab, CD3XBCMA BITE: A singlecenter experience. Proceedings of the International Myeloma Society Annual Meeting and Exposition, Athens, Greece.","DOI":"10.1016\/S2152-2650(23)01642-7"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/blood-2023-180660","article-title":"Teclistamab in Relapsed Refractory Multiple Myeloma Patients on Dialysis: A French Experience","volume":"142","author":"Lachenal","year":"2023","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Harrell, S., de Coella, J.-M.S., Sonntag, C., and Cazaubiel, T. (2023, January 17\u201330). P-014 teclistamab in relapsed and refractory multiple myeloma: Patients characteristics from post marketing acces (acces precoce) in France. Proceedings of the Internation Myeloma Society Annual Meeting and Exposition, Athens, Greece.","DOI":"10.1016\/S2152-2650(23)01632-4"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1200\/JCO.2024.42.16_suppl.7515","article-title":"Class comparison of BCMA-directed therapies in relapsed multiple myeloma","volume":"42","author":"Rees","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_77","unstructured":"Sandahl, T.B., Soefje, S.A., Calay, E.S., Lin, Y., Fonseca, R., Ailawadhi, S., Parrondo, R., Lin, D., Wu, B., and Silvert, E. (2024, January 3\u20136). Real-World Treatment Outcomes of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration. Proceedings of the Hematology\/Oncology Pharmacy Association 2024, Tampa, FL, USA."},{"key":"ref_78","first-page":"1","article-title":"BCMA x CD3 bispecifc antibody treatment with teclistamab in relapsed and\/or refractory multiple myeloma: A real-world monocentric analysis","volume":"46","author":"Schaefers","year":"2023","journal-title":"Oncol. Res. Treat."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"11146","DOI":"10.1200\/JCO.2024.42.16_suppl.11146","article-title":"Ambulatory teclistamab administration in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Tabbara","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood-2023-178896","article-title":"Real-World Patient Profile and Step-up Dosing Process of Early Initiators of Teclistamab for Multiple Myeloma in US Hospitals\u2014An Updated Analysis Using Premier Healthcare Database","volume":"142","author":"Tan","year":"2023","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"S509","DOI":"10.1016\/S2152-2650(23)01471-4","article-title":"MM-595 Feasibility and Safety of Outpatient Model for Teclistamab Step-Up Dosing Administration: A Single Center Experience","volume":"23","author":"Yanovsky","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e20044","DOI":"10.1200\/JCO.2023.41.16_suppl.e20044","article-title":"Efficacy of teclistamab in patients (pts) with heavily pretreated, relapsed\/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA (B-cell maturation antigen) directed therapy (BDT)","volume":"41","author":"Venkatesh","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1235\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:10:48Z","timestamp":1760029848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":82,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cancers17071235"],"URL":"https:\/\/doi.org\/10.3390\/cancers17071235","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]}}}